Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more
Luye Pharma Group Ltd (LYPHF) - Total Liabilities
Latest total liabilities as of June 2025: $15.49 Billion USD
Based on the latest financial reports, Luye Pharma Group Ltd (LYPHF) has total liabilities worth $15.49 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Luye Pharma Group Ltd - Total Liabilities Trend (2003–2024)
This chart illustrates how Luye Pharma Group Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Luye Pharma Group Ltd Competitors by Total Liabilities
The table below lists competitors of Luye Pharma Group Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Oneness Biotech Co Ltd
TWO:4743
|
Taiwan | NT$872.39 Million |
|
Hyosung TNC Corp
KO:298020
|
Korea | ₩3.78 Trillion |
|
Shenzhen Sunwin Intelligent
SHE:300044
|
China | CN¥1.03 Billion |
|
Cohort plc
F:C7K
|
Germany | €247.03 Million |
|
MNC Studios International Tbk PT
JK:MSIN
|
Indonesia | Rp1.07 Trillion |
|
Wuxi Hodgen Technology Co Ltd
SHE:300279
|
China | CN¥896.79 Million |
|
Malaysian Pacific Industries
KLSE:3867
|
Malaysia | RM690.97 Million |
|
Yunding Technology Co Ltd
SHE:000409
|
China | CN¥826.07 Million |
Liability Composition Analysis (2003–2024)
This chart breaks down Luye Pharma Group Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Luye Pharma Group Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Luye Pharma Group Ltd (2003–2024)
The table below shows the annual total liabilities of Luye Pharma Group Ltd from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $13.86 Billion | +15.85% |
| 2023-12-31 | $11.96 Billion | -9.43% |
| 2022-12-31 | $13.21 Billion | -1.93% |
| 2021-12-31 | $13.47 Billion | +7.47% |
| 2020-12-31 | $12.53 Billion | +26.05% |
| 2019-12-31 | $9.94 Billion | +3.51% |
| 2018-12-31 | $9.60 Billion | +148.54% |
| 2017-12-31 | $3.86 Billion | +46.17% |
| 2016-12-31 | $2.64 Billion | +110.94% |
| 2015-12-31 | $1.25 Billion | +14.65% |
| 2014-12-31 | $1.09 Billion | -26.62% |
| 2013-12-31 | $1.49 Billion | +36.20% |
| 2012-12-31 | $1.09 Billion | +4.17% |
| 2011-12-31 | $1.05 Billion | +82.93% |
| 2010-12-31 | $573.98 Million | +33.72% |
| 2009-12-31 | $429.24 Million | +75.30% |
| 2008-12-31 | $244.86 Million | -31.37% |
| 2007-12-31 | $356.76 Million | +221.21% |
| 2006-12-31 | $111.07 Million | +155.40% |
| 2005-12-31 | $43.49 Million | -51.50% |
| 2004-12-31 | $89.67 Million | -47.37% |
| 2003-12-31 | $170.38 Million | -- |